Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology
Allosteric modulation
Publications
Partners & collaboration
Investors
Addex Corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
11.03
2009
Addex Presents ADX10059 PD-LID Data at GPCR Drug Discovery Conference
09.28
2009
Addex completes enrollment of first mid-stage clinical GERD trial
09.17
2009
Laurent Massuyeau, Head of Business Development, Resigns
09.14
2009
Addex’ ADX10059 has potential for Parkinson’s disease levodopa induced dyskinesia (PD-LID)
07.28
2009
Addex Pharmaceuticals Reports First Half 2009 Financial Results
07.23
2009
Addex First Half 2009 Financial Results Tuesday, July 28
07.16
2009
Addex R&D Day Highlights Broadened Therapeutic Potential of Allosteric Modulation Platform to Include Cytokine Receptors as well as GPCRs
07.10
2009
Addex Achieves Second Milestone in Parkinson’s Disease Collaboration with Merck & Co., Inc.
07.02
2009
Addex to Host R&D Day on July 16
06.24
2009
Addex Partner Starts First-Ever Clinical Trial of an mGluR Positive Allosteric Modulator novel approach has potential for treatment of multiple cns disorders
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Next
Back